Core Scientific (CORZ) Cash & Equivalents (2021 - 2026)

Core Scientific (CORZ) has 6 years of Cash & Equivalents data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Cash & Equivalents rose 44.02% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 44.02% YoY) and the FY2025 annual result came in at $311.4 million, down 62.76% from the prior year.
• Cash & Equivalents grew to $1.0 billion in Q1 2026 per CORZ's latest filing, from $311.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.0 billion in Q1 2026, with the low at $15.9 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $282.4 million, with a median of $98.1 million recorded in 2024.
• The widest YoY moves for Cash & Equivalents: up 6186.29% in 2022, down 86.52% in 2022.
• Core Scientific's Cash & Equivalents stood at $15.9 million in 2022, then jumped by 217.36% to $50.4 million in 2023, then jumped by 1558.83% to $836.2 million in 2024, then tumbled by 62.76% to $311.4 million in 2025, then jumped by 222.81% to $1.0 billion in 2026.
• Business Quant data shows CORZ's Cash & Equivalents at $1.0 billion in Q1 2026, $311.4 million in Q4 2025, and $453.4 million in Q3 2025.